On 21st July 2025, Suzhou Ribo Life Science Co., Ltd. ("Ribo"), a global leader in siRNA therapeutics, announced the successful completion of its Series E financing round, raising over RMB 200 million (approximately US$28 million). The round was led by Mingxin Capital, with participation from prominent investors including Kunshan High-Tech VC, Kunshan Guokai VC, Chouqin VC, Panlin Capital, Everest VC, and Shenzhen Xinchuang Yihe.

The proceeds will accelerate clinical development across cardiovascular, metabolic, renal, and hepatic disease pipelines while advancing the Company's proprietary extrahepatic delivery technology platform. The capital injection will further strengthen Ribo’s  global R&D capabilities and industrial infrastructure. Since inception, Ribo has raised over RMB 1.8 billion (∼US$250 million) from top-tier investors, evolving from a pioneer in China's oligonucleotide space to a global siRNA frontrunner. With strategic R&D centers in Suzhou, Beijing (China) and Gothenburg  (Europe), the Company has established an integrated development system covering the entire siRNA drug lifecycle – from discovery to commercialisation.

Dr. Zicai Liang, Chairman and CEO, emphasized: "With our investors' steadfast support, Ribo has achieved transformative breakthroughs in both platform technologies and clinical pipelines. We remain committed to global leadership through our dual-engine strategy combining international product development and proprietary innovation."

Dr. Lixing Xu, Founding Partner of Mingxin Capital, noted: "siRNA represents the most disruptive modality in biopharma today, offering superior dosing frequency, patient compliance, and development efficiency compared to traditional therapies. As the category leader with multiple clinical-stage assets, Ribo's world-class team exemplifies global excellence. We're proud to lead this round through Jinan Mingxin Industrial Investment Fund and will actively support their international expansion." 

Click here for the full article.